You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

Practical Clinical Insights on New Combination Paradigms in HR-Positive Advanced Breast Cancer

  • Authors: Sibylle Loibl, MD, PhD
  • CPD Released: 3/22/2017
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 3/22/2018
Start Activity


Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US healthcare professionals, specifically oncologists, obstetricians/gynecologists, and pathologists involved in the treatment of patients with hormone receptor (HR)-positive advanced breast cancer.

The goal of this activity is to improve physicians' understanding regarding the use of cyclin-dependent kinase (CDK) 4/6 inhibitors in combination with endocrine therapy for treating HR-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer patients.

Upon completion of this activity, participants will:

  • Have greater competence related to the role of CDK 4/6 inhibition for HR-positive, HER2-negative advanced breast cancer patients
  • Have greater competence related to the recognition and management of AEs associated with the use of CDK 4/6 inhibitors in HR-positive, HER2-negative advanced breast cancer patients


Disclosures

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.


Moderator(s)

  • Sibylle Loibl, MD, PhD

    Co-Chair, German Breast Group, Sana Kliniken Offenbach, Breast Cancer Center; Associate Professor, University Frankfurt am Main, Frankfurt, Germany

    Disclosures

    Disclosure: Sibylle Loibl, MD, PhD, has disclosed the following relevant financial relationships:
    Received grants for clinical research from: Amgen Inc.; AstraZeneca Pharmaceuticals LP; Celgene Corporation; Novartis Pharmaceuticals Corporation; Pfizer Inc; Roche; Teva Europe

Steering Committee

  • Nadia Harbeck, MD, PhD

    Professor, Breast Center, Department of Obstetrics and Gynecology, University of Munich (LMU), Munich, Germany

    Disclosures

    Disclosure: Nadia Harbeck, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Pfizer Inc
    Served as a speaker or a member of a speakers bureau for: Novartis Pharmaceuticals Corporation; Pfizer Inc

  • Javier Cortés, MD, PhD

    Head, Breast Cancer and Gynecological Tumours, Ramón y Cajal University Hospital, Oncology Department, Madrid, Spain; Clinical Investigator, Breast Cancer Research Program, Vall d’Hebron Institute of Oncology, Barcelona, Spain

    Disclosures

    Disclosure: Javier Cortés, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bi
    Othera Pharmaceuticals, Inc.; Celgene Corporation; Cellestia Biotech; Roche
    Served as a speaker or a member of a speakers bureau for: Celgene Corporation; Eisai Co., Ltd; Novartis Pharmaceuticals Corporation; Pfizer Inc; Roche

  • Angelo Di Leo, MD, PhD

    Head, Medical Oncology Unit; Chair, Oncology Department, "Sandro Pitigliani" Medical Oncology Unit - Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy

    Disclosures

    Disclosure: Angelo Di Leo, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bayer HealthCare Corporation; Celgene Corporation; Eisai Co., Ltd; Genomic Health; Ipsen; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Pfizer Inc; Pierre Fabre; Roche

  • Stephen R.D. Johnston, MA, FRCP, PhD

    Professor of Breast Cancer Medicine, Royal Marsden Hospital, London, United Kingdom

    Disclosures

    Disclosure: Stephen R.D. Johnston, MA, FRCP, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Novartis Pharmaceuticals Corporation; Pfizer Inc; Puma Biotechnology; Roche
    Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; GlaxoSmithKline; Pfizer Inc; Puma Biotechnology
    Received grants for clinical research from: GlaxoSmithKline; Pfizer Inc

  • Xavier Pivot, MD, PhD

    Professor, J Minjoz University Hospital, Besancon, France

    Disclosures

    Disclosure: Xavier Pivot, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Amgen Inc.; Novartis Pharmaceuticals Corporation; Roche
    Served as a speaker or a member of a speaker's bureau for: Eisai Co., Ltd; Novartis Pharmaceuticals Corporation; Roche

  • Sunil Verma, MD, MSEd, FRCPC

    Professor, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada

    Disclosures

    Disclosure: Sunil Verma, MD, MSEd, FRCPC, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Novartis Pharmaceuticals Corporation; Pfizer Inc; Roche

Editors

  • Deborah Middleton, MS

    Scientific Director, WebMD Global, LLC

    Disclosures

    Disclosure: Deborah Middleton, MS, has disclosed no relevant financial relationships.

  • Kathryn M. O'Rourke, BA, MA

    Medical Writer, WebMD Global, LLC

    Disclosures

    Disclosure: Kathryn M. O'Rourke, BA, MA, has disclosed no relevant financial relationships.

Content Reviewer

  • Robert Morris, PharmD

    Associate CME Clinical Director

    Disclosures

    Disclosure: Robert Morris, PharmD, has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 1.00 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

Practical Clinical Insights on New Combination Paradigms in HR-Positive Advanced Breast Cancer

Authors: Sibylle Loibl, MD, PhDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CPD Released: 3/22/2017

Valid for credit through: 3/22/2018

processing....